TransMedics stock lifts 2026 revenue outlook after Q3 growth
Published on 11/13/2026 at 00:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth and Clinical Catalysts
- Third-quarter revenue rose 41 percent year over year to 203.0 million US dollars.
- TransMedics raised its full-year 2026 revenue guidance to 764 million to 774 million US dollars including PAD Aviation.
- FDA approvals for ENHANCE Heart Part B and DENOVO Lung support the company's planned expansion into new indications.
TransMedics reported record third-quarter revenue and case volume on November 5, while raising its full-year 2026 outlook. The company also pointed to regulatory progress in heart and lung transplantation and continued expansion in Europe.
According to the TransMedics financial release, third-quarter revenue reached 203.0 million US dollars, up 41 percent from the year-earlier period. Product revenue increased 29 percent to 113.4 million US dollars, while service revenue rose 60 percent to 89.6 million US dollars.
Net income was 17.1 million US dollars, or 0.46 US dollars per diluted share. Adjusted net income was 18.9 million US dollars, or 0.51 US dollars per diluted share. Gross margin edged down to 58.5 percent from 58.8 percent as the revenue mix shifted toward services, while operating expenses rose with investments in clinical programs, infrastructure and expansion.
Higher Guidance, New Trial Milestones
TransMedics lifted its full-year revenue guidance to 764 million to 774 million US dollars, including about 14 million US dollars from PAD Aviation. Excluding that contribution, the range is 750 million to 760 million US dollars, compared with the previous range of 737 million to 757 million US dollars.
The company completed enrollment in Part A of the ENHANCE Heart trial and received FDA approval for a continued access protocol. It also received investigational device exemption approvals for ENHANCE Heart Part B and DENOVO Lung. Management expects these programs to support growth opportunities from 2027, alongside planned European launches of the Organ Care System in Italy, the Netherlands and Belgium.
Current TransMedics Stock Quote
TransMedics stock traded at 83.04 euros on Lang & Schwarz at 11:00 p.m. CET on Thursday, November 12, 2026.
Organ Preservation Technology
TransMedics is a commercial-stage medical technology company headquartered in the United States. It develops the Organ Care System, which maintains donor organs in a functioning environment outside the body and supports assessment and preservation for transplantation. Its focus covers end-stage heart, lung and liver failure, with logistics services and clinical programs supporting broader adoption. The company is expanding its transplant platform through new indications, organ preservation technology and European operations.
TransMedics Group at a Glance
- Company: TransMedics Group, Inc.
- ISIN: US89377M1099
- Ticker: TMDX
- Listing: Nasdaq
- Lang & Schwarz quote: 83.04 euros on November 12, 2026, at 11:00 p.m. CET
- Third-quarter revenue: 203.0 million US dollars for the period ended September 30, 2026
- Full-year 2026 revenue guidance: 764 million to 774 million US dollars including PAD Aviation
Broader market context is available in the S&P 500 market coverage.
More news and analyses on TransMedics stock.
